Biomaterial Collection - and Analysis in Cardiac Sarcoidosis

Launched by HEART CENTER LEIPZIG - UNIVERSITY HOSPITAL · Mar 30, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a condition called cardiac sarcoidosis (CS), which involves inflammation in the heart. The study aims to better understand the disease's causes and find new ways to diagnose it. Currently, diagnosing CS can be tricky, as it often looks similar to other heart issues, leading to delays in treatment. The researchers will collect and analyze samples from patients' blood, heart tissue, and lymph nodes to learn more about the disease and identify potential new markers that could help with diagnosis and treatment.

To participate in the trial, individuals must have a history of cardiac sarcoidosis, inflammatory heart disease, or certain heart-related symptoms that may suggest CS. Additionally, patients who need a heart assist device or transplantation due to suspected heart issues may also be eligible. Participants will provide consent for their samples to be used in this research, and they can expect to contribute to important discoveries that could improve how cardiac sarcoidosis is diagnosed and treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (a) patients with a history of symptomatic cardiac sarcoidosis/inflammatory cardiomyopathy or b) patients with newly diagnosed heart failure with cardiac arrhythmias (ventricular tachycardia, conduction disturbances, etc.) that may indicate sarcoidosis or inflammatory cardiomyopathy or c) patients with image morphological suspicion of cardiac sarcoidosis or inflammatory cardiomyopathy (MRI, PET-CT) or (d) patients who require or have received a ventricular assist device (VAD) or cardiac transplantation due to suspected cardiac sarcoidosis or inflammatory cardiomyopathy and (e) written informed consent has been obtained from patients for study participation and consent for analysis of patient samples. Studies on pseudoanonymized samples will only be performed with appropriately signed informed consent.
• Exclusion Criteria:
• • 1. Patients with psychiatric illness that impairs business or insight capacity.
• • 2. Patients with chronic heart failure due to coronary artery disease or valvular vitiation.
• • 3. severe underlying disease other than sarcoidosis that is likely to result in death within one year.